Blackstone to sell Japanese drugmaker Alinamin for $2.17 billion

2024-07-02 03:21:45

Asia Tech Wire (July 2) -- U.S. private equity firm Blackstone is to sell Japanese drugmaker Alinamin Pharmaceutical to Asian investment fund MBK Partners for 350 billion yen ($2.17 billion), according to Nikkei.

Alinamin was formerly the Japanese consumer healthcare division of Takeda Pharmaceutical (TOKYO:4502, NYSE:TAK).

The division's flagship products include Alinamin, Japan's first vitamin B1 derivative, and a cold remedy called Benza.

In April 2021, Takeda announced the completion of the sale of the business to Blackstone for a total transaction value of 242 billion yen.

Blackstone Japan

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Tencent Holdings repurchased 3.93 million shares for HK$1.5 billion on January 7
                            2025-01-07

                                    Ireland recorded a 12.8 billion euro fiscal surplus last year due to the "Apple tax" ruling
                            2025-01-07

                                    Ministry of Industry and Information Technology: Promoting technical verification of 10G optical network and artificial intelligence integration
                            2025-01-07

                                    Tencent's major shareholder Prosus reduced its stake in Tencent Holdings from 24.01% to 23.99% on January 6.
                            2025-01-07

                                    U.S. chip stocks rose before the market opened, with Nvidia up 0.6%
                            2025-01-07